DRUG
Price
$35.99
Change
-$0.16 (-0.44%)
Updated
Feb 21 closing price
Capitalization
253.03M
ORYZF
Price
$1.57
Change
+$0.01 (+0.64%)
Updated
Feb 10 closing price
Capitalization
201.46M
Ad is loading...

DRUG vs ORYZF

Header iconDRUG vs ORYZF Comparison
Open Charts DRUG vs ORYZFBanner chart's image
Bright Minds Biosciences
Price$35.99
Change-$0.16 (-0.44%)
Volume$62.47K
Capitalization253.03M
Oryzon Genomics SA
Price$1.57
Change+$0.01 (+0.64%)
Volume$687
Capitalization201.46M
DRUG vs ORYZF Comparison Chart
Loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DRUG vs. ORYZF commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Hold and ORYZF is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (DRUG: $35.99 vs. ORYZF: $1.58)
Brand notoriety: DRUG and ORYZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 77% vs. ORYZF: 27%
Market capitalization -- DRUG: $253.03M vs. ORYZF: $201.46M
DRUG [@Biotechnology] is valued at $253.03M. ORYZF’s [@Biotechnology] market capitalization is $201.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whileORYZF’s FA Score has 1 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • ORYZF’s FA Score: 1 green, 4 red.
According to our system of comparison, both DRUG and ORYZF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 3 TA indicator(s) are bullish.

  • DRUG’s TA Score: 3 bullish, 7 bearish.

Price Growth

DRUG (@Biotechnology) experienced а -13.90% price change this week, while ORYZF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

DRUG is expected to report earnings on Aug 28, 2023.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DRUG($253M) has a higher market cap than ORYZF($201M). DRUG YTD gains are higher at: -0.083 vs. ORYZF (-2.778). ORYZF has higher annual earnings (EBITDA): 834K vs. DRUG (-3.54M). ORYZF has more cash in the bank: 8.44M vs. DRUG (6.19M). DRUG has less debt than ORYZF: DRUG (14K) vs ORYZF (13.4M). DRUG (0) and ORYZF (0) have equivalent revenues.
DRUGORYZFDRUG / ORYZF
Capitalization253M201M126%
EBITDA-3.54M834K-425%
Gain YTD-0.083-2.7783%
P/E RatioN/AN/A-
Revenue00-
Total Cash6.19M8.44M73%
Total Debt14K13.4M0%
TECHNICAL ANALYSIS
Technical Analysis
DRUG
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COO88.48-0.21
-0.24%
Cooper Companies (The)
DXLG2.36-0.01
-0.42%
Destination XL Group
SPRB0.42-0.01
-1.20%
Spruce Biosciences
IBOC63.97-1.75
-2.66%
International Bancshares Corp
ERII14.65-0.83
-5.36%
Energy Recovery

ORYZF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORYZF has been loosely correlated with CLDI. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORYZF jumps, then CLDI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORYZF
1D Price
Change %
ORYZF100%
N/A
CLDI - ORYZF
37%
Loosely correlated
-16.67%
PPBT - ORYZF
28%
Poorly correlated
-2.46%
DRUG - ORYZF
25%
Poorly correlated
-0.44%
GNNSF - ORYZF
24%
Poorly correlated
+23.18%
IPSC - ORYZF
20%
Poorly correlated
-2.51%
More